CN110684044B - 一种制备Tubulysin关键片段Tuv的方法 - Google Patents
一种制备Tubulysin关键片段Tuv的方法 Download PDFInfo
- Publication number
- CN110684044B CN110684044B CN201810748596.1A CN201810748596A CN110684044B CN 110684044 B CN110684044 B CN 110684044B CN 201810748596 A CN201810748596 A CN 201810748596A CN 110684044 B CN110684044 B CN 110684044B
- Authority
- CN
- China
- Prior art keywords
- compound
- organic solvent
- tuv
- dissolving
- tubulysin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930184737 tubulysin Natural products 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000012634 fragment Substances 0.000 title claims abstract description 19
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 72
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- 239000003960 organic solvent Substances 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 229940125782 compound 2 Drugs 0.000 claims description 12
- -1 methyl ester compound Chemical class 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 11
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 229940125898 compound 5 Drugs 0.000 claims description 10
- 239000007800 oxidant agent Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- LHBLJWULWKQRON-UHFFFAOYSA-N (2-nitrophenyl) selenocyanate Chemical compound [O-][N+](=O)C1=CC=CC=C1[Se]C#N LHBLJWULWKQRON-UHFFFAOYSA-N 0.000 claims description 5
- 239000002841 Lewis acid Substances 0.000 claims description 5
- 150000007517 lewis acids Chemical class 0.000 claims description 5
- 150000007530 organic bases Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 229940065287 selenium compound Drugs 0.000 claims description 5
- 150000003343 selenium compounds Chemical class 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 3
- OKGGRXMKBJLXHI-UHFFFAOYSA-N lithium;triethoxyalumane Chemical compound [Li].CCO[Al](OCC)OCC OKGGRXMKBJLXHI-UHFFFAOYSA-N 0.000 claims description 3
- KVRSDIJOUNNFMZ-UHFFFAOYSA-L nickel(2+);trifluoromethanesulfonate Chemical compound [Ni+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F KVRSDIJOUNNFMZ-UHFFFAOYSA-L 0.000 claims description 3
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 claims description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- UCYRAEIHXSVXPV-UHFFFAOYSA-K bis(trifluoromethylsulfonyloxy)indiganyl trifluoromethanesulfonate Chemical compound [In+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F UCYRAEIHXSVXPV-UHFFFAOYSA-K 0.000 claims description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 2
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- DDCWGUIPLGMBPO-UHFFFAOYSA-K samarium(3+);trifluoromethanesulfonate Chemical compound [Sm+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F DDCWGUIPLGMBPO-UHFFFAOYSA-K 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 13
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- 229930014626 natural product Natural products 0.000 abstract description 4
- WUFZLLWTTGBSDH-HHKQAZDGSA-N (2s,4r)-4-[[2-[(1r,3r)-1-hydroxy-4-methyl-3-[[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-phenylpentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N[C@H](C[C@@H](O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C WUFZLLWTTGBSDH-HHKQAZDGSA-N 0.000 abstract description 3
- 108010058859 tubulysin V Proteins 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical group CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 241000863009 Archangium gephyra Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000863004 Cystobacter Species 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229930000438 bacterial secondary metabolite Natural products 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LCEFEIBEOBPPSJ-UHFFFAOYSA-N phenyl selenohypobromite Chemical compound Br[Se]C1=CC=CC=C1 LCEFEIBEOBPPSJ-UHFFFAOYSA-N 0.000 description 1
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于化学合成技术领域,涉及一种制备具有抗癌活性天然产物Tubulysin的关键片段Tuv的方法。本发明方法操作简单,路线简洁,收率较高,尤其本发明方法的技术路线高选择性、可放大制备Tubulysin V的Tuv片段。本发明方法制得的具有抗癌活性天然产物Tubulysin的关键片段Tuv有助于该类化合物的成药性评价及临床前评价。
Description
技术领域
本发明属于化学合成技术领域,涉及具有抗癌活性天然产物Tubulysin的Tuv片段高效制备方法
背景技术
资料显示癌症已成为严重威胁人类健康的重大疾病之一。据世界卫生组织2014年发布癌症报告资料显示:2012年全球癌症新增病例和死亡人数出现惊人的增长,全球有1400万新增癌症病例,死亡人数达到820万;中国已成为癌症发病大国,2012年新增癌症病例多达350万,死亡人数250万。在癌症的治疗方案中,化学药物治疗一直是最重要的手段之一。有报道公开了Tubulysins(Figure 1)是从黏细菌Archangium gephyra和Angiococcusdisciformis中提取得到的细菌次生代谢产物(Antibiot.2000,53:879-885),具有很强的抗癌活性,其细胞毒性是紫杉醇的20-1000倍,如,Tubulysin V对60多种癌细胞的GI50值小(GI50=0.059nM),远远低于紫杉醇的GI50(GI50=1.95nM)和长春碱的GI50(GI50=0.94nM)。
Figure 1Tubulysins的结构
Tubulysins作用的靶点是微管蛋白,其通过阻止微管蛋白的聚合从而裂解癌细胞的细胞骨架并介导细胞凋亡;研究显示,Tubulysins的抗癌活性的机理是:阻止微管蛋白聚合使细胞周期停滞,在细胞有丝分裂微管形成纺锤体的过程中Tubulysins标定到微管蛋白上,阻止微管蛋白的聚合、从而抑制有丝分裂过程中纺锤体的形成,最终抑制有丝分裂和介导细胞凋亡。另有研究报道,Tubulysins对P-糖蛋白过度表达的人KB-V宫颈癌细胞系具有很好的抗癌活性(IC50=0.31nM),表现出Tubulysin V具有抗多药耐药性(MDR)活性。
由于天然产物Tubulysins优异的抗癌活性及优异的抗多耐药性活性,自分离以来饱受国内外的合成化学家和药物化学家的青睐,诸多的不对称合成方法已经发表((a).Angew.Chem.Int.Ed.2007,46,2337-2348.(b).Angew.Chem.Int.Ed.2007,46,3526-3529.(c).J.Med.Chem.2009,52,238-240.(d).Chem.Eur.J.2010,16,11678-11688.(e).Chin.J.Chem.2013,31,40-48.(f).Chem.Asian J.2013,8,1213-1222.(g).J.Org.Chem.2016,81,10302-10320.(h).J.Am.Chem.Soc.2018,140,3690-3711.),然而,由于Tubulysins家族分子中,均具有两个手性孤立的直链片段,这为其制备带来了极大的困难,使诸多已报道的文献方法难用于进一步药理学评价级的制备,给该类化合物的成药性评价及临床前评价带来很大的困难.因此,条件温和制备Tubulysins诸片段及类分子的合成方法在本领域仍然具有很大的挑战。
基于现有技术的现状和有关Tubulysins的高效合成研究(Tetrahedron 2016,72,5928-5933)基础上,本申请的发明人拟提供一种Tuv片段的高选择性合成新方法。
发明内容
本发明的目的旨在提供Tubulysins分子关键Tuv片段高选择性制备技术路线,具体涉及一种制备Tubulysin关键片段Tuv的方法。本方法可以高效、低成本、可放大制备Tuv片段。
本发明所涉及的Tubulysins分子关键Tuv片段按下述技术路线制备::
在下文的陈述中,中间体通式是根据结构式中的编号,用阿拉伯数字表示。P表示氮原子的保护基,具体为Boc、Cbz,COOMe或COOEt,P1表示氧原子保护基,具体为TBS、TES、TBDPS、Bn、PMB、Ac,R、R1和R2表示不同芳基或烷基取代基。
具体的,本发明的制备Tubulysin的关键片段Tuv的方法按下述技术路线和步骤:
步骤1:化合物1溶于有机溶剂中,在-78℃至50℃之间用还原剂还原1-10小时,后处理得到化合物2;
步骤2:在-78℃至0℃的有机溶剂中,加入有机碱和不同基团取代的甲基酮或醛,搅拌10-30分钟后加入Lewis酸反应0.5-1.5h后,缓慢加入化合物2,反应0.5-2h后经后处理得化合物3;
步骤3:化合物3溶于一种有机溶剂中,在-78℃至50℃之间用一种还原剂还原1-10小时,后处理得到化合物4;
步骤4:化合物4和一种硒化合物溶于一种有机溶剂中,在0℃至30℃加入一种配位磷试剂,0.5-2.5h后,将体系置于-20℃至30℃,并加入一种氧化剂,反应0.5-4h后进行后处理得到化合物5;
步骤5:氮气保护下将化合物5溶于一种有机溶剂,加入钯/碳,置换氢气后室温反应0.5-3h后处理得到化合物6;
步骤6:化合物6溶于一种有机溶剂,在0℃至30℃加入一种氧化剂,反应5-20h后处理得到化合物7;
步骤7,化合物7通过开环得到甲酯化合物,还原得到醇,再经swern氧化,再与L-半胱氨酸甲酯对接制得Tubulysin的Tuv片段。
本发明中,步骤1:化合物1溶于有机溶剂中,在-78℃至50℃之间用还原剂还原1-10小时,经后处理得到化合物2。这里所说的一种有机溶剂指甲醇、二氯甲烷、四氢呋喃,特别是四氢呋喃。所说的一种还原剂指三乙氧基氢化铝锂、氰基硼氢化钠、硼烷二甲硫醚、四氢铝锂或三乙基硼氢化锂等,特别是三乙基硼氢化锂。
本发明中,步骤2:在-78℃至0℃的有机溶剂中,加入有机碱和不同基团取代的甲基酮或醛,搅拌十分钟后加入Lewis酸反应0.5-1.5h后,缓慢加入化合物2,反应0.5-2h后经后处理后得到化合物3。这里所说的有机溶剂指四氢呋喃、乙腈、二氯乙烷、二氯甲烷、环己烷或正己烷,特别是二氯甲烷。所说的有机碱指咪唑、三乙胺、乙二胺或异丙胺等,特别是异丙胺和三乙胺。所说的Lewis酸指三氟甲磺酸镍、三氟甲磺酸酮、三氟甲磺酸三甲基硅酯、四氯化钛、三氟化硼乙醚、三氟甲磺酸钐或三氟甲磺酸铟,特别是三氟甲磺酸三甲基硅酯。
本发明中,步骤3:化合物3溶于一种有机溶剂中,在-78℃至50℃之间用一种还原剂还原1-10小时,后处理得到化合物4。这里所说的一种溶剂指四氢呋喃、甲醇或二氯甲烷,特别是甲醇。所说的一种还原剂指硼氢化钾、硼氢化钠、硼氢化锂、腈基硼氢化钠、四氢铝锂或三乙基硼氢化锂,特别是硼氢化钾或硼氢化钠。
本发明中,步骤4:化合物4和一种硒化合物溶于一种有机溶剂中,在0℃至30℃加入一种配位磷试剂,0.5-2.5h后,将体系置于-20℃至30℃,并加入一种氧化剂,反应0.5-4h后进行后处理得到化合物5。这里所说的一种硒化合物指2-硝基苯基硒氰酸酯、苯基溴化硒,苯基氯化硒等,特别是2-硝基苯基硒氰酸酯。所说的一种有机溶剂是指四氢呋喃、甲醇、乙腈或二氯甲烷,特别是四氢呋喃。所说的一种配位磷试剂是指三丁基膦,三苯基膦,特别是三丁基膦。所说的一种氧化剂是指过氧化氢,高碘酸钠,特别是过氧化氢。
本发明中,步骤5:氮气保护下将化合物5和溶于一种有机溶剂,加入钯/碳,置换氢气后室温反应0.5-3h后处理得到化合物6。这里所说的一种有机溶剂是指甲醇,乙醇,乙酸乙酯,二氯甲烷,特别是甲醇和乙酸乙酯。
本发明中,步骤6:化合物6溶于一种有机溶剂,在0℃至30℃加入一种氧化剂,反应5-20h后处理得到化合物7。这里所说的一中有机溶剂是指乙酸乙酯,二氯甲烷,四氢呋喃,乙腈/四氯化碳/,乙酸乙酯/水,乙腈/水,特别是乙腈/四氯化碳/水和乙酸乙酯/水。所说的一种氧化剂是指过氧化苯甲酰,3-氯过氧苯甲酸,叔丁基过氧化氢,高碘酸钠/三氯化钌,高碘酸钠/二氧化钌,硝酸铈铵,特别是高碘酸钠/三氯化钌。
本发明中,化合物1可根据文献方法制备(Tetrahedron,2000,56,7705-7713),Tubulysin的Tuv片段合成可参照文献方法制备(Tetrahedron,2016,72,5928-5933)。
本发明提供了一种制备Tubulysin关键片段Tuv的方法,该方法操作简单,路线简洁,收率较高,所用的试剂均为常用试剂,尤其所述技术路线低成本、高选择性、可放大制备高光学活性Tubulysin。
具体实施方式
实施例1
步骤1:合成化合物2(P=Boc,P1=TBS)
化合物1(2.0g,6.30mmol)溶于干燥四氢呋喃(25mL),在-78℃滴加LiEt3BH(15mL,15.75mmol,1.0M in THF),反应30分钟后MeOH(5mL)淬灭,5分钟后加入饱和碳酸氢钠溶液,升至室温,乙酸乙酯萃取三次,合并有机相,饱和食盐水洗一次,无水硫酸镁干燥,过滤浓缩,柱层析得到浅黄色油状液体化合物2(1.91g,95%);
步骤2:合成化合物3(R1=CH3,R2=H)
在-78℃下的二氯甲烷(8.0mL)中,加入三乙胺(0.47mL,3.40mmol))和丙醛(0.17mL,2.36mmol),搅拌15分钟后加入TMSOTf(1.00mL,5.50mmol),反应30分钟后,将溶于二氯甲烷(3.0mL)的化合物2(500mg,1.57mmol)滴加到上述反应体系中,反应1h后加入饱和碳酸氢钠淬灭,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到无色油状液体化合物3(396mg,71%)。1H NMR(400MHz,CDCl3,isomers,rotamers)δ9.81-9.63(m,1H),4.39-4.27(m,1H),4.23-4.09(m,0.8H),4.04-3.94(m,0.2H),3.87-3.74(m,0.5H),3.72-3.62(m,0.5H),3.30-2.80(m,2H),2.32-2.05(m,1H),1.87-1.64(m,1H),1.47-1.43(m,9H),1.23-1.21(m,0.2H),1.13-1.09(m,0.8H),1.08-1.04(m,1.5H),1.04-0.99(m,0.5H),0.88(s,9H),0.06(s,6H)ppm.
步骤3:合成化合物4
化合物3(396mg,1.11mmol)溶于干燥MeOH(6mL),0℃加入NaBH4(105mg,2.78mmol),搅拌30分钟后,饱和氯化铵淬灭,并蒸干溶剂,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到浅黄色油状液体化合物4(400mg,100%);
步骤4:合成化合物5
化合物4(198mg,0.55mmol)和2-硝基苯基硒氰酸酯(250mg,1.10mmol)溶于干燥四氢呋喃(8mL),室温下加入Bu3P(0.27mL,1.10mmol),反应45分钟后于0℃加入H2O2(30%,4mL),反应2.5h后,用水淬灭体系,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩(20℃)后经硅胶柱层析得到浅黄色油状液体化合物5(99mg,53%)。1H NMR(400MHz,CDCl3,rotamers)δ4.85-4.71(m,2H),4.30-4.21(m,1.4H),4.19-4.10(m,0.6H),3.86-3.77(m,0.6H),3.76-3.67(m,0.4H),3.12(dd,J=10.9,6.6Hz,1H),2.32-2.22(m,1H),1.71-1.67(m,4H),1.47-1.43(m,3.6H),1.42-1.38(m,5.4H),0.87(s,9H),0.05(s,6H)ppm.
步骤5:合成化合物6
氮气保护下将化合物5(53mg,0.16mmol)和100%钯/碳(53mg)溶于甲醇,置换氢气后室温反应2h后过硅胶漏斗,浓缩柱层析得到浅黄色油状液体化合物6(49mg,92%)。1HNMR(400MHz,CDCl3,rotamers)δ4.33-4.17(m,1H),3.93-3.84(m,0.6H),3.78-3.60(m,1.4H),2.93(dd,J=11.0,6.9Hz,1H),2.43-2.19(m,1H),2.07-1.96(m,1H),1.77-1.59(m,1H),1.45(s,9H),0.87(s,9H),0.91-0.87(m,9H),0.86-0.82(m,5.6H),0.77-0.74(m,0.4H),0.06(s,6H)ppm.
步骤6:合成化合物7
化合物6(23mg,0.067mmol)溶于乙酸乙酯(1mL),氮气保护下加入NaIO4(43mg,0.20mmol)and RuCl3·nH2O(3mg,0.013mmol)的水溶液(1mL),反应18后,异丙醇淬灭,蒸干有机溶剂,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩(20℃)后经硅胶柱层析得到黄色油状液体化合物7(11mg,46%)。1H NMR(400MHz,CDCl3)δ4.26(dd,J=8.8,8.0Hz,1H),3.95-3.87(m,1H),2.60-2.48(m,1H),2.25-2.15(m,1H),1.68-1.58(m,1H),1.53(s,9H),0.92-0.88(m,12H),0.80(d,J=6.9Hz,1H),0.17(s,3H),0.13(s,3H)ppm.
步骤7:Tubulysin的Tuv片段合成
化合物7(526mg,1.47mmol)溶于甲醇(13mL),加入碳酸钾(203mg,1.47mmol).,室温反应过夜,饱和氯化铵淬灭,旋蒸除去有机相,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩柱层析得到无色油状化合物(504mg,88%)。此无色油状化合物(382mg,0.98mmol)溶于干燥四氢呋喃(10mL),于0℃下滴加三乙基硼氢化锂(2.5mL,2.45mmol,1.0M in THF)反应5分钟后MeOH(5mL)淬灭,5分钟后加入饱和碳酸氢钠溶液,乙酸乙酯萃取三次,合并有机相,饱和食盐水洗一次,无水硫酸镁干燥,过滤浓缩,柱层析得到浅黄色油状液体化合物(269mg,76%)。干燥二氯甲烷(8mL)中加入(COCl)2(0.15mL,1.78mmol),并降至-78℃,滴加DMSO(0.25mL,3.56mmol)的二氯甲烷溶液(6mL),-78℃反应1小时后,滴加上述浅黄色油状液体化合物(322mg,0.89mmol)的DCM(8mL)溶液,-78℃反应3小时后,加入TEA(0.74mL,5.34mmol)淬灭,升至室温,45分钟后,加入L-半胱氨酸甲酯酸盐(367mg,2.23mmol)的乙醇溶液(8mL),反应3小时候,后处理得到黄色油状化合物(291mg,77%)。此油状化合物(682mg,1.43mmol)溶于干燥乙腈(15mL),在75℃下经两次二氧化锰(2.87gX2,14.3mmolx2)氧化得到Tubulysin的Tuv片段(352mg,52%)。8.10(s,1H),7.39-7.32(m,2H),7.28-7.23(m,2H),7.22-7.15(m,1H),5.22-5.15(m,1H),4.73-4.65(m,2H),3.93(s,3H),3.68(brs,1H),2.07-1.97(m,1H),1.94-1.80(m,2H),1.76-1.67(m,1H),1.42(s,9H),0.84(s,9H),0.81(s,9H),0.04(s,3H),-0.02(s,3H),-0.16(s,3H),-0.24(s,3H)ppm.
实施例2
步骤1:合成化合物2(P=Boc,P1=TBS)
化合物1(2.0g,6.30mmol)溶于干燥四氢呋喃(25mL),在-78℃滴加NaBH3CN(0.91mL,15.75mmol),反应30分钟后MeOH(5mL)淬灭,5分钟后加入饱和碳酸氢钠溶液,升至室温,乙酸乙酯萃取三次,合并有机相,饱和食盐水洗一次,无水硫酸镁干燥,过滤浓缩,柱层析得到浅黄色油状液体化合物2(1.91g,95%);
步骤2:合成化合物3(R1=CH3,R2=H)
在-78℃下的二氯甲烷(8.0mL)中,加入三乙胺(0.47mL,3.40mmol))和丙醛(0.17mL,2.36mmol),搅拌15分钟后加入Cu(OTf)2(1.81g,5.50mmol),反应30分钟后,将溶于二氯甲烷(3.0mL)中的化合物4(500mg,1.57mmol)滴加到上述反应体系中,反应1h后加入饱和碳酸氢钠淬灭,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到无色油状液体化合物3(396mg,71%)。1H NMR(400MHz,CDCl3,isomers,rotamers)δ9.81-9.63(m,1H),4.39-4.27(m,1H),4.23-4.09(m,0.8H),4.04-3.94(m,0.2H),3.87-3.74(m,0.5H),3.72-3.62(m,0.5H),3.30-2.80(m,2H),2.32-2.05(m,1H),1.87-1.64(m,1H),1.47-1.43(m,9H),1.23-1.21(m,0.2H),1.13-1.09(m,0.8H),1.08-1.04(m,1.5H),1.04-0.99(m,0.5H),0.88(s,9H),0.06(s,6H)ppm.
步骤3:合成化合物4
化合物2(396mg,1.11mmol)溶于干燥MeOH(6mL),0℃加入KBH4(150mg,2.78mmol),搅拌30分钟后,饱和氯化铵淬灭,并蒸干溶剂,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到浅黄色油状液体化合物4(400mg,100%);
步骤4:合成化合物5
化合物4(198mg,0.55mmol)和2-硝基苯基硒氰酸酯(250mg,1.10mmol)溶于干燥四氢呋喃(8mL),室温下加入Bu3P(0.27mL,1.10mmol),反应45分钟后于0℃加入高碘酸钠(118mg,0.55mmol),反应2.5h后,用水淬灭体系,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩(20℃)后经硅胶柱层析得到浅黄色油状液体化合物5(99mg,53%)。1HNMR(400MHz,CDCl3,rotamers)δ4.85-4.71(m,2H),4.30-4.21(m,1.4H),4.19-4.10(m,0.6H),3.86-3.77(m,0.6H),3.76-3.67(m,0.4H),3.12(dd,J=10.9,6.6Hz,1H),2.32-2.22(m,1H),1.71-1.67(m,4H),1.47-1.43(m,3.6H),1.42-1.38(m,5.4H),0.87(s,9H),0.05(s,6H)ppm.
步骤5:合成化合物6
氮气保护下将化合物5(53mg,0.16mmol)和100%钯/碳(53mg)溶于乙酸乙酯(3mL),置换氢气后室温反应2h后过硅胶漏斗,浓缩柱层析得到浅黄色油状液体化合物6(49mg,92%)。1H NMR(400MHz,CDCl3,rotamers)δ4.33-4.17(m,1H),3.93-3.84(m,0.6H),3.78-3.60(m,1.4H),2.93(dd,J=11.0,6.9Hz,1H),2.43-2.19(m,1H),2.07-1.96(m,1H),1.77-1.59(m,1H),1.45(s,9H),0.87(s,9H),0.91-0.87(m,9H),0.86-0.82(m,5.6H),0.77-0.74(m,0.4H),0.06(s,6H)ppm.
步骤6:合成化合物7
化合物6(23mg,0.067mmol)溶于乙酸乙酯(1mL),氮气保护下加入NaIO4(43mg,0.20mmol)and RuO2·nH2O(2mg,0.013mmol)的水溶液(1mL),反应18后,异丙醇淬灭,蒸干有机溶剂,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩后经硅胶柱层析得到黄色油状液体化合物7(11mg,46%)。1H NMR(400MHz,CDCl3)δ4.26(dd,J=8.8,8.0Hz,1H),3.95-3.87(m,1H),2.60-2.48(m,1H),2.25-2.15(m,1H),1.68-1.58(m,1H),1.53(s,9H),0.92-0.88(m,12H),0.80(d,J=6.9Hz,1H),0.17(s,3H),0.13(s,3H)ppm.
步骤7:Tubulysin的Tuv片段合成
同实施例1。
实施例3
步骤1:合成化合物2(P=Boc,P1=TBS)
化合物1(2.0g,6.30mmol)溶于干燥四氢呋喃(25mL),在-78℃滴加三乙氧基氢化铝锂(2.68g,15.75mmol),反应30分钟后MeOH(5mL)淬灭,5分钟后加入饱和碳酸氢钠溶液,升至室温,乙酸乙酯萃取三次,合并有机相,饱和食盐水洗一次,无水硫酸镁干燥,过滤浓缩,柱层析得到浅黄色油状液体化合物2(1.91g,95%)。
步骤2:合成化合物3(R1=CH3,R2=H)
在-78℃下的二氯甲烷(8.0mL)中,加入三乙胺(0.47mL,3.40mmol))和丙醛(0.17mL,2.36mmol),搅拌15分钟后加入三氟甲磺酸镍(1.96g,5.50mmol),反应30分钟后,将溶于二氯甲烷(3.0mL)中的化合物4(500mg,1.57mmol)滴加到上述反应体系中,反应1h后加入饱和碳酸氢钠淬灭,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到无色油状液体化合物3(396mg,71%)。1H NMR(400MHz,CDCl3,isomers,rotamers)δ9.81-9.63(m,1H),4.39-4.27(m,1H),4.23-4.09(m,0.8H),4.04-3.94(m,0.2H),3.87-3.74(m,0.5H),3.72-3.62(m,0.5H),3.30-2.80(m,2H),2.32-2.05(m,1H),1.87-1.64(m,1H),1.47-1.43(m,9H),1.23-1.21(m,0.2H),1.13-1.09(m,0.8H),1.08-1.04(m,1.5H),1.04-0.99(m,0.5H),0.88(s,9H),0.06(s,6H)ppm.
步骤3:合成化合物4
化合物2(396mg,1.11mmol)溶于干燥MeOH(6mL),0℃加入LiBH4(61mg,2.78mmol),搅拌30分钟后,饱和氯化铵淬灭,并蒸干溶剂,乙酸乙酯萃取三次,合并有机相用饱和食盐水洗涤,干燥,浓缩经硅胶柱层析得到浅黄色油状液体化合物4(400mg,100%)。
步骤4、5、6,7同实施例1。
Claims (8)
1.一种制备Tubulysin关键片段Tuv的方法,其特征在于,按下述路线合成:
其中,P1为二甲基叔丁基硅基,P为Boc保护基,R1为甲基,R2为氢;
包括步骤:
步骤1:化合物1溶于有机溶剂中,在-78℃至50℃之间用还原剂还原1-10小时,后处理得到化合物2;
步骤2:在-78℃至0℃的有机溶剂中,加入有机碱和不同基团取代的甲基酮或醛,搅拌10-30分钟后加入Lewis酸反应0.5-1.5h后,缓慢加入化合物2,反应0.5-2h后经后处理得化合物3;
步骤3:化合物3溶于一种有机溶剂中,在-78℃至50℃之间用一种还原剂还原1-10小时,后处理得到化合物4;
步骤4:化合物4和一种硒化合物溶于一种有机溶剂中,在0℃至30℃加入一种配位磷试剂,0.5-2.5h后,将体系置于-20℃至30℃,并加入一种氧化剂,反应0.5-4h后进行后处理得到化合物5;
步骤5:氮气保护下将化合物5溶于一种有机溶剂,加入钯/碳,置换氢气后室温反应0.5-3h后处理得到化合物6;
步骤6:化合物6溶于一种有机溶剂,在0℃至30℃加入一种氧化剂,反应5-20h后处理得到化合物7;
步骤7,化合物7通过开环得到甲酯化合物,还原得到醇,再经swern氧化后,与L-半胱氨酸甲酯对接制得Tubulysin的Tuv片段。
2.按权利要求1所述的方法,其特征在于,步骤1所述的还原剂是三乙氧基氢化铝锂、氰基硼氢化钠、硼烷二甲硫醚、四氢铝锂或三乙基硼氢化锂。
3.按权利要求1所述的方法,其特征在于,步骤2所述的有机溶剂是四氢呋喃、乙腈、二氯乙烷、二氯甲烷、环己烷或正己烷。
4.按权利要求1所述的方法,其特征在于,步骤2所述的有机碱是咪唑、三乙胺、乙二胺或异丙胺。
5.按权利要求1的方法,其特征在于,步骤2所述的Lewis酸是三氟甲磺酸镍、三氟甲磺酸酮、三氟甲磺酸三甲基硅酯、四氯化钛、三氟化硼乙醚、三氟甲磺酸钐或三氟甲磺酸铟。
6.按权利要求1所述的方法,其特征在于,步骤4所述的硒化合物是2-硝基苯基硒氰酸酯、苯基溴化硒或苯基氯化硒;所述的氧化剂是过氧化氢或高碘酸钠。
7.按权利要求1所述的方法,其特征在于,步骤5所述的有机溶剂是甲醇。
8.按权利要求1所述的方法,其特征在于,步骤6所述有机溶剂是乙酸乙酯,所述的氧化剂是高碘酸钠/三氯化钌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810748596.1A CN110684044B (zh) | 2018-07-06 | 2018-07-06 | 一种制备Tubulysin关键片段Tuv的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810748596.1A CN110684044B (zh) | 2018-07-06 | 2018-07-06 | 一种制备Tubulysin关键片段Tuv的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110684044A CN110684044A (zh) | 2020-01-14 |
CN110684044B true CN110684044B (zh) | 2022-08-26 |
Family
ID=69107077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810748596.1A Active CN110684044B (zh) | 2018-07-06 | 2018-07-06 | 一种制备Tubulysin关键片段Tuv的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110684044B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111647040B (zh) * | 2020-05-11 | 2022-02-22 | 深圳市老年医学研究所 | 一种天然活性多肽Tubulysin U的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333133A (zh) * | 2013-06-13 | 2013-10-02 | 西北师范大学 | 一种Tubulysin家族化合物关键中间体TUV的合成方法 |
US20170290878A1 (en) * | 2014-09-25 | 2017-10-12 | Endocyte, Inc. | Methods of treating cancer with tubulysin conjugates |
-
2018
- 2018-07-06 CN CN201810748596.1A patent/CN110684044B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333133A (zh) * | 2013-06-13 | 2013-10-02 | 西北师范大学 | 一种Tubulysin家族化合物关键中间体TUV的合成方法 |
US20170290878A1 (en) * | 2014-09-25 | 2017-10-12 | Endocyte, Inc. | Methods of treating cancer with tubulysin conjugates |
Non-Patent Citations (3)
Title |
---|
An efficient method for the preparation of 3-hydroxyl-5-substituted 2-pyrrolidones and application in the divergent synthesis of (-)-preussin and its analogues;Qian-Ru Zhou等;《Tetrahedron》;20140516;第70卷;第4799-4808页 * |
An enantioselective total synthesis of tubulysin V;Wei Tao等;《Tetrahedron》;20160815;第72卷;第5928-5933页 * |
Total Synthesis of Tubulysins U and V;Monica Sani等;《Angew. Chem. Int. Ed.》;20070402;第46卷;第3526-3529页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110684044A (zh) | 2020-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jalce et al. | Diastereoselective synthesis of 2, 5-disubstituted tetrahydrofurans | |
JP2024037931A (ja) | カンタリジンおよび生理活性カンタリジン誘導体の商業的に実現可能な合成 | |
CN110684044B (zh) | 一种制备Tubulysin关键片段Tuv的方法 | |
Pal et al. | Benzoxazole alkaloids: occurrence, chemistry, and biology | |
Fehlhaber et al. | Structure of aranorosin, a new antibiotic of a novel skeletal type | |
Lu et al. | Syntheses of two diastereoisomers of panaxytriol, a potent antitumor agent isolated from panax ginseng | |
Tius et al. | A Concise Synthesis of d, l-Methylenomycin A and d, l-epi-Methylenomycin A | |
TWI527805B (zh) | 由紅果椌木半日花烷製備降龍涎香醚及由紅果椌木製備新穎二萜類化合物 | |
CN108299339B (zh) | 甜菊苷衍生物及其制备方法和用途 | |
CN103012422A (zh) | 一种5,11-亚甲基吗吩烷啶化合物制备及应用 | |
Giorgi et al. | A one-pot sequence for the efficient synthesis of highly functionalized macrocarbocycles or bridged 2, 8-dioxabicyclo [3.2. 1] octanes from 1-nitrobicyclic compounds | |
Wallfisch et al. | 2, 6, 9-Trioxabicyclo [3.3. 1] nona-3, 7-dienes and 2, 4, 6, 8-Tetraoxaadamantanes: Novel Chiral Spacer Units in Macrocyclic Polyethers | |
Luchetti et al. | Enantio-and Diastereodivergent Synthetic Route to Multifarious Cyclitols from D-Xylose via Ring-Closing Metathesis | |
Comanita et al. | A mild route to α‐alkoxyacetylenes mediated by lewis acids and synthetic routes to 10‐, 11‐, and 12‐membered ring enediyne carbocycles | |
CN113788734B (zh) | 一种(1S,2S,4S)-β-榄香烯的合成方法及其中间体 | |
CN114773303B (zh) | 一种抗癌药物先导物木脂素Aglacin B的制备方法 | |
WO2021249545A1 (zh) | 一步法制备具有反式稠合多聚环醚骨架结构的聚醚的方法 | |
CN110684036B (zh) | 一条制备甲磺酸艾日布林的方法 | |
Geddis | The Total Synthesis of Pseudonocardia sp. Quinolone Natural Products and Studies Towards the Total Synthesis of 1β-Hydroxyalantolactone | |
Barker | Studies towards the total synthesis of phyllaemblic acid | |
CN108484554B (zh) | 一种抗锥虫、抗癌天然产物Cryptofolione的合成方法 | |
Montaña et al. | Introduction of a new stereocenter on C1-functionalized 8-oxabicyclo [3.2. 1] oct-6-en 3-ones by a regio-and stereoselective electrophilic addition. Obtention of polyfunctionalized cycloheptanes with five stereocenters | |
Šimek | Tandem Anionic Sigmatropic Rearrangement/Radical Reactions and Their Application Toward the Total Synthesis of Natural Products | |
Taylor | Total synthesis of nemorosone and nemorosone II | |
Lin et al. | New Dioxa‐Cage and Diacetal Trioxa‐Cage Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |